| Literature DB >> 32759918 |
Anna Krueger, Jayleen K L Gunn, Joanna Watson, Andrew E Smith, Rebecca Lincoln, Sara L Huston, Emilio Dirlikov, Sara Robinson.
Abstract
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is spread from person to person (1-3). Quarantine of exposed persons (contacts) for 14 days following their exposure reduces transmission (4-7). Contact tracing provides an opportunity to identify contacts, inform them of quarantine recommendations, and monitor their symptoms to promptly identify secondary COVID-19 cases (7,8). On March 12, 2020, Maine Center for Disease Control and Prevention (Maine CDC) identified the first case of COVID-19 in the state. Because of resource constraints, including staffing, Maine CDC could not consistently monitor contacts, and automated technological solutions for monitoring contacts were explored. On May 14, 2020, Maine CDC began enrolling contacts of patients with reported COVID-19 into Sara Alert (MITRE Corporation, 2020),* an automated, web-based, symptom monitoring tool. After initial communication with Maine CDC staff members, enrolled contacts automatically received daily symptom questionnaires via their choice of e-mailed weblink, text message, texted weblink, or telephone call until completion of their quarantine. Epidemiologic investigations were conducted for enrollees who reported symptoms or received a positive SARS-CoV-2 test result. During May 14-June 26, Maine CDC enrolled 1,622 contacts of 614 COVID-19 patients; 190 (11.7%) eventually developed COVID-19, highlighting the importance of identifying, quarantining, and monitoring contacts of COVID-19 patients to limit spread. In Maine, symptom monitoring was not feasible without the use of an automated symptom monitoring tool. Using a tool that permitted enrollees to specify a method of symptom monitoring was well received, because the majority of persons monitored (96.4%) agreed to report using this system.Entities:
Mesh:
Year: 2020 PMID: 32759918 PMCID: PMC7454893 DOI: 10.15585/mmwr.mm6931e2
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Characteristics of contacts* of confirmed or probable COVID-19 patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) — Maine, May 14–June 26, 2020
| Characteristic | No. (%) |
|---|---|
|
|
|
|
| 29 (0–93) |
|
| |
| Female | 766 (50.3) |
| Male | 757 (49.7) |
| Not reported | 99 (—) |
|
| |
| American Indian/Alaska Native | 5 (0.4) |
| Asian/Pacific Islander | 17 (1.4) |
| Black/African American | 486 (39.2) |
| White | 732 (59.0) |
| Not reported | 382 (—) |
|
| |
| Hispanic or Latino | 42 (4.1) |
| Not Hispanic or Latino | 978 (95.9) |
| Not reported | 602 (—) |
|
| |
| American Sign Language | 6 (0.5) |
| Arabic | 8 (0.7) |
| English | 985 (80.1) |
| French | 86 (7.0) |
| Kirundi | 8 (0.7) |
| Lingala | 11 (0.9) |
| Portuguese | 10 (0.8) |
| Somali | 81 (6.6) |
| Spanish | 19 (1.5) |
| Other | 16 (1.4) |
| Not reported | 392 (—) |
|
| |
| Androscoggin | 421 (26.9) |
| Aroostook | 39 (2.5) |
| Cumberland | 713 (45.6) |
| Franklin | 12 (0.8) |
| Hancock | 2 (0.3) |
| Kennebec | 60 (3.8) |
| Knox | 1 (0.1) |
| Lincoln | 8 (0.5) |
| Oxford | 32 (2.1) |
| Penobscot | 17 (1.1) |
| Sagadahoc | 25 (1.6) |
| Somerset | 9 (0.6) |
| Waldo | 3 (0.2) |
| Washington | 14 (0.9) |
| York | 193 (12.4) |
| Out of state | 10 (0.6) |
| Missing | 59 (—) |
Abbreviation: COVID-19 = coronavirus disease 2019.
* Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29).
† Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell.
Enrollment details and monitoring preferences among contacts* of confirmed or probable COVID-19 patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) — Maine, May 14–June 26, 2020
| Characteristic | No. (%) |
|---|---|
|
|
|
|
| |
| 0 | 153 (9.5) |
| 1 | 47 (2.9) |
| 2 | 275 (17.1) |
| 3 | 153 (9.5) |
| 4 | 208 (12.9) |
| 5 | 166 (10.3) |
| 6 | 163 (10.1) |
| ≥7 | 447 (27.7) |
| Missing date of last exposure | 10 (—) |
|
| |
| E-mailed weblink | 119 (7.3) |
| Text message | 976 (60.2) |
| Texted weblink | 342 (21.1) |
| Telephone call | 127 (7.8) |
| Direct monitoring§ | 58 (3.6) |
|
| |
| Morning | 479 (32.5) |
| Afternoon | 126 (8.5) |
| Evening | 870 (59.0) |
| Not recorded | 147 (—) |
|
| |
| 1 | 673 (70.6) |
| 2 | 125 (13.1) |
| 3 | 75 (7.9) |
| 4 | 33 (3.5) |
| 5 | 21 (2.2) |
| ≥6 | 27 (2.7) |
Abbreviation: COVID-19 = coronavirus disease 2019.
* Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29).
† Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell.
§ Direct monitoring refers to contacts who did not want to be, or could not be, enrolled for automated monitoring. For these contacts, Maine CDC staff members called contacts daily until the end of their quarantine period.
¶ Based on address reported at time of enrollment.
Characteristics of contacts* of confirmed or probable COVID-19 patients enrolled in an automated, web-based symptom monitoring tool (Sara Alert) who developed COVID-19 during quarantine—Maine, May 14–June 26, 2020
| Characteristic | No. (%)§ |
|---|---|
|
|
|
|
| |
| Confirmed | 127 (66.8) |
| Probable | 63 (33.2) |
|
| |
| Yes | 136 (74.3) |
| No | 47 (25.7) |
| Missing | 7 (—) |
|
| 32 (0–93) |
|
| |
| Female | 99 (52.1) |
| Male | 91 (47.9) |
|
| |
| Asian/Pacific Islander | 3 (1.6) |
| Black/African American | 81 (43.5) |
| White | 98 (52.7) |
| Other | 4 (2.2) |
| Unknown | 4 (—) |
|
| |
| Hispanic or Latino | 6 (3.3) |
| Not Hispanic or Latino | 176 (96.7) |
| Missing | 8 (—) |
|
| |
| Household | 112 (67.9) |
| Community | 29 (17.6) |
| Health care | 26 (15.8) |
| Unknown | 25 (—) |
|
| |
| Yes | 4 (2.1) |
| No | 186 (97.9) |
|
| |
| Yes | 1 (0.5) |
| No | 189 (99.5) |
Abbreviation: COVID-19 = coronavirus disease 2019.
* Defined as persons who were within 6 feet of an infectious person (symptomatic persons, 2 days before symptom onset to at least 10 days following symptom onset; asymptomatic persons, 2 days before collection of a specimen that resulted in a positive test to 10 days following specimen collection date) for ≥15 minutes (≥30 minutes before May 29).
† Probable cases had either clinical criteria or epidemiologic evidence of exposure (contact with a person with a confirmed or probable COVID-19 case or contact with a person with clinically compatible illness or linkage to a person with confirmed COVID-19), or met vital records criteria (a death certificate listing COVID-19 or SARS-CoV-2 as a cause of death or a significant condition contributing to death with no confirmatory laboratory testing performed for COVID-19). Confirmed cases had confirmatory laboratory evidence of SARS-CoV-2 infection. COVID-19 signs and symptoms included cough, difficulty breathing, fever, chills, shaking with chills (rigors), muscle pain, headache, sore throat, and new loss of taste or smell.
§ Percentage calculated among enrollees with nonmissing information.
¶ Two contacts reported multiple exposure types.